GlassScriptPhysician profile
Remberto Santos
NPI 1396075057
$3,691.55
in general payments reported to CMS, 2019-2025
21 companies · $219 in 2025
The $219 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,352 · 2020: $252 · 2021: $446 · 2022: $36.00 · 2023: $258 · 2024: $128 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $604.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,554.85 | 2019 | |
| Exeltis, USA INC. | $746.63 | 2019-2025 | Slynd |
| Abbvie INC. | $400.70 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Coloplast Corp | $137.14 | 2021 | |
| Hologic Sales and Service, LLC | $120.22 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Mayne Pharma Commercial LLC | $114.73 | 2019-2023 | |
| Coopersurgical, INC. | $113.85 | 2021-2025 | |
| Becton, Dickinson and Company | $111.59 | 2024-2025 | Bd Onclarity |
| Allergan, INC. | $86.46 | 2019-2020 | |
| Pfizer INC. | $82.09 | 2023 | |
| Sumitomo Pharma America, INC. | $42.48 | 2023 | Myfembree |
| Dysis Medical, INC. | $26.78 | 2019-2020 | |
| Astellas Pharma US INC | $23.89 | 2025 | Veozah |
| Therapeuticsmd, INC. | $21.25 | 2021 | |
| Evofem Biosciences, INC. | $20.12 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $19.53 | 2020 | |
| Mission Pharmacal Company | $18.91 | 2021 | |
| Duchesnay USA Incorporated | $17.38 | 2019 | |
| Lupin INC. | $16.83 | 2020 | |
| Daiichi Sankyo INC. | $16.12 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Remberto Santos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.